Zolpidem therapy for movement disorders

Recent Patents on CNS Drug Discovery

Volumn 3, Issue 1, 2008, Pages 55-60

  Abe, Kazuo ^a,b  

^a KONAN WOMEN'S UNIVERSITY   (Japan)

^b Konan Hospital   (Japan)

Author keywords

Gamma aminobutyric acid (GABA); Movement disorders; Parkinson's disease; Progressive supranuclear palsy (PSP); Zolpidem

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMANTADINE; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR AGONIST; NEUROLEPTIC AGENT; PERGOLIDE; PLACEBO; PRAMIPEXOLE; QUINOLONE DERIVATIVE; TRIAZOLAM; ZOLPIDEM; ZOPICLONE;

APHASIA; BALANCE IMPAIRMENT; BASAL GANGLION; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; DEMENTIA; DIAGNOSTIC VALUE; DOSE RESPONSE; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; GABAERGIC TRANSMISSION; HUMAN; MOTOR DYSFUNCTION; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIDOTOMY; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RECEPTOR DENSITY; RESTLESS LEGS SYNDROME; SHORT SURVEY; SINGLE DRUG DOSE; SPINOCEREBELLAR DEGENERATION; TARDIVE DYSKINESIA; THERAPY RESISTANCE;

ANIMALS; GABA AGONISTS; HUMANS; MOVEMENT DISORDERS; PYRIDINES;

EID: 38949126125     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488908783421519     Document Type: Short Survey

References (62)

1. Depoortere H, Zivkovic B, Lloyd KG, et al. Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 1986; 237: 649-658
2. Panile A, Albanese A, Gainotti G, Gregori B, Bartolomeo P. Zolpidem in Parkinson's disease. Lancet 1997; 349: 1222-1223.
3. Langer SZ, Arbilla S, Scatton BV, Niddam R, Dubois A. Receptors involved in the mechanism of action of zolpidem. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders: a novel experiment and therapeutic approach. New York: Raven Press, 1988: 55-70.
4. Cavalheiro, EA, Olney JW. Glutamate antagonists: Deadly liaisons with cancer.. Proc Natl Acad Sci USA 2001; 98: 5947-5948.
5. Tarsy D. Dystonia. In: Ahlskog JE, Adler CH, eds. Parkinson's disease and movement disorders: diagnosis and treatment guidelines for the practicing physician. Totowa, NJ: Humana Press, 2000; 297-311.
6. Jankovic J, Marsden CD. Therapeutic strategies in Parkinson's disease. In: J Jankovic and E Tolosa, Editors, Parkinson's disease and movement disorders, Urban and Schwarzenberg, Baltimore and Munich 1988; 95-119.
7. Grafton ST, Waters C, Sutton J, Lew MF, Couldwell W. Pallidotomy increases activity of motor association cortex in Parkinson's disease: a positron emission tomographic study. Ann Neurol 1995; 37: 776-783.
8. Calon F, Di Paolo T. Levodopa response motor complications GABA receptors and preproenkephalin expression in human brain. Parkinsonism Relat Disord 2002; 8: 449-454.
9. Montgomery EB.Jr. Effect of subthalamic nucleus stimulation patterns on motor performance in Parkinson's disease. Parkinsonism Relat Disord 2005; 11: 167-171.
10. Chen L, Xie J-X, Fung K-S, Yung W-H. Zolpidem modulates GABAA receptor function in subthalamic nucleus. Neurosci Res 2007; 58: 77-85
11. Farver DK, Khan MH. Zolpidem for antipsychotic-induced parkinsonism. Ann Pharmacother 2001; 35: 435-437.
12. Müller T. Drug treatment of non-motor symptoms in Parkinson's disease. Expert Opin Pharmacother 2002; 3: 381-388.
13. Abe K. Tiredness and fatigue. J Int Soc Life Inform Sci 2006; 24: 60-62.
14. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. Arch Neurol 1964; 10: 333-359.
15. Litvan I, Agid Y, Caine D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47:1-9.
16. Albers DS, Augood SJ. New insights into progressive supranuclear palsy. Trends Neurosci 2001; 24:347-53.
17. Nath UB-SY, Thomson RG, Lees AJ, et al. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003; 25:910-16.
18. Goetz CG, Leurgans S, Lang AE, et al. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology 2003; 60:917-22.
19. Abe K. Hummingbird and squint eyes in progressive supranuclear palsy. Int Med 2006; 45: 935-93.
20. Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 2002; 17: 1255-64
21. Levy R, Ruberg M, Herrero MT, et al. Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy: an in situ hybridization study of GAD67 messenger RNA. Neurology 1995; 45:127-34.
22. Fabbrini G, Barbanti P, Bonifati V, et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand 2001; 103:123-25.
23. Foster NL, Aldrich Ms, Bluemlein L, et al. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 1989; 39:257-61.
24. Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001; 57:467-73
25. Warren NW, Piggott MA, Lees AJ, Burn DJ. The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases. J Neurol Neurosurg Psychiatry 2007; 78: 571-575.
26. Foster NL, Minoshima S, Johanns J, et al. PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology 2000; 54:1768-1773.
27. Heiss WD, Herholz K. Brain Receptor Imaging. J Nucl Med 2006; 47: 302-312.
28. Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear patsy. N Engl J Med 1999; 341: 543-544.
29. Daniele A, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med 1999: 341, 1632.
30. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Caine DB, eds. Recent developments in Parkinson's disease, vol 2. Florham Park, NJ: MacMillan Healthcare Information, 1987; 2:153-163.
31. Evidente VGH. Zolpidem improves dystonia in "Lubag" or X-linked dystonia-parkinsonism syndrome. Neurology 2001; 58: 662-663.
32. Tarsy D. Dystonia. In: Ahlskog JE, Adler CH, eds. Parkinson's disease and movement disorders: diagnosis and treatment guidelines for the practicing physician. Totowa, NJ: Humana Press, 2000; 297-311.
33. Nobrega JN, Richter A, McIntyre BW, Löscher W. Alterations in the brain GABAA/benzodiazepine receptor-chloride ionophore complex in a genetic model of paroxysmal dystonia: a quantitative autoradiographic analysis. Neuroscience 1995; 64: 229-239.
34. Langer SZ, Arbilla S, Scatton BV, Niddam R, Dubois A. Receptors involved in the mechanism of action of zolpidem. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. NewYork: Raven Press, 1988; 55-70.
35. Brandish, P.E., Brandon, N., Campbell, A., Sparey, T., WO07093829 (2007).
36. Garretto NS, Bueri JA, Rey RD, Arakaki T, Nano GV, Mancuso M. Improvement of blepharospasm with zolpidem. Mov Disord 2004; 19: 967-968.
37. Ruzicka E, Roth J, Jech R, Busek P. Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease. Mov Disord 2000; 15: 734-735.
38. Vitek JL, Chockkan V, Zhang J-Y. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballism. Ann Neurol 1999; 46: 22-35.
39. Berardelli A, Rothwell JC, Hallett M, et al. The pathophysiology of primary dystonia. Brain 1998; 121: 1195-1212.
40. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy, and tolerability in the treatment of insomnia: Drugs 2000; 59: 865-889.
41. Shipe, W.D., Lindsley, C., Hallett, D.: WO07100366 (2007).
42. Bezerra MLS, Martinez J-VL. Zolpidem in restless legs syndrome. Eur Neurol 2002; 48: 180-181.
43. The International Restless Legs Syndrome Study Group: Toward a better definition of the restless legs syndrome. Mov Disord 1995; 10:634-642.
44. Chokroverty S, Jankovic J. Restless legs syndrome: A disease in search of identity. Neurology 1999; 53: 907-910.
45. Montplaisir J, Nicolas A, Denese R, Gomez-Mantilla B. Restless legs syndrome improved by pramipexole: A double-blind randomized trial. Neurology 1999; 52: 938-943.
46. Turjanski N, Lees A J, Brooks DJ: Striatal dopaminergic function in restless legs syndrome. IBF-dopa and IC-raclopride PET studies. Neurology 1999; 52:932-937.
47. Ruottinen HM, Partinen M, Hublin C, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000; 54: 502-504.
48. Niddam R, Dubois A, Scotton B, Arbilla S, Langer SZI. Autoradiographic localization of [3H]zolpidem binding sites in the rat CNS: Comparison with the distribution of [3H]flunitrazepam binding sites. J Neurochem 1987; 49: 890
49. Clauss R, Sathekge M, Net W. Transient improvement of spinocerebellar ataxia with zolpidem. N Engl J Med 2004; 351: 511.
50. Pulst S-M. Spinocerebellar ataxia type 2 (SCA2). Animal models. Mov Disord 2005; 631-636.
51. Orozco DG, Estrada R, Perry T, Araña J, Fernández R. Dominantly inherited olivopontocerebellar atrophy from eastern Cuba. Clinical, neuropathological and biochemical findings, J Neurol Sci 1989; 93: 37-50.
52. Huynh DP, Yang HT, Vakharia H, Nguyen D, Pulst S-M. Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. Hum Mol Genet 2003; 12:1485-1496.
53. Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration Annu Rev Neurosci 2000; 23: 217-247.
54. Estrada R, Galarraga J, Orozco G, et al. Spinocerebellar ataxia 2 (SCA2) morphometric analyses in 11 autopsies characterize it as an olivo-ponto-cerebellar atrophy (OPCA) plus. Acta Neuropathol 1999; 97: 306-310.
55. Rüb U, Del Turco D, Del Tredici K, et al. Thalamic ivolvement in a spinocerebellar ataxia type 2 (SCA2) and spinocerebellar type 3 (SCA3) patient and its clinical relevance. Brain 2003; 126: 1-16.
56. Bishnoi M, Chopra K, Kulkarni SK, et al. Possible antioxidant and neuroprotective mechanisms of Zolpidem in attenuating neuroleptic-induced orofacial dyskinesia-A biochemical and neurochemical study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1130-1138.
57. Cohen L, Chaaban B, Habert MO. Transient improvement of aphasia with zolpidem. N Engl J Med 2004; 350: 511.
58. Ginsberg DL. Zoipidem Treatment of Chronic Aphasia. Prim Psychiatry 2004; 11: 12.
59. Müller U, Von Cramon DY. The therapeutic potential of bromocriptine in neuropsychological rehabilitation of patients with acquired brain damage. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 1103-1120.
60. de Boissezon X, Peran P, de Boysson C, Démonet J-F. Pharmacotherapy of aphasia: Myth or reality? Brain Lang 2007, 102: 114-125.
61. Lipshutz, B.H.: WO07095631 (2007).
62. Chapdelaine, M., Ohnmacht, C., Becker, C., Chang, H-F., Dembofsky, B.: WO07073283 (2007).